艾伯维Q2业绩超预期 上调全年调整后每股收益指引

Core Viewpoint - AbbVie reported a 6.6% year-over-year revenue growth to $15.42 billion, exceeding analyst expectations of $15.03 billion [1] - Adjusted earnings per share (EPS) were $2.97, also above the forecasted $2.88 [1] Revenue Breakdown - Global sales of the immunology drug Humira fell 58% to $1.18 billion, with a more significant decline in the U.S. market [1] - Strong sales performance from the new arthritis drug Skyrizi, with global sales soaring 62% to $4.42 billion [1] Future Guidance - AbbVie expects adjusted EPS for the year to be between $11.88 and $12.08, an increase from the previous estimate of $11.67 to $11.87 [1]